Capio's Nomination Committee in Respect of the Annual General Meeting 2018
GÖTEBORG, Sweden, October 12, 2017 /PRNewswire/ --
The Nomination Committee of Capio AB (publ) in respect of the Annual General Meeting 2018, appointed in accordance with the instruction resolved by the Annual General Meeting on May 11, 2016, consists of:
Mikael Moll, appointed by Zeres Capital (Chairman of the nomination committee)
Michael Wolf (the Chairman of the Board)
Per Hesselmark, appointed by R12 Kapital
Bo Lundgren, appointed by Swedbank Robur fonder
Per Colleen, appointed by Fjärde AP-fonden
Jan Särlvik, appointed by Nordea Funds
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee on the address below or by e-mail [email protected]. To ensure that a proposal can be considered by the Nomination Committee such proposal must have been received by the Nomination Committee in due time before the Annual General Meeting, which will be held in Gothenburg on 3 May, 2018.
Capio AB (publ) The Nomination Committee c/o Box 1064 SE-405 22 Göteborg
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed...
Lowell Farms Inc. (the "Company") , a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces audited revenue and operating results for the fourth...
All Star Healthcare Solutions®, a full-service healthcare staffing company specializing in locum tenens and direct-hire opportunities for physicians, nurse practitioners, physician assistants, and certified registered nurse anesthetists, was named a...
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of...
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity
Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024
Received Safety Review Committee (SRC) Approval...
Breckenridge Brewery ("Breckenridge" or the "Brewery"), a pioneer in Colorado's craft beer scene, and a subsidiary of Tilray Brands, Inc. , announced today an exciting partnership with the Denver Nuggets to launch a celebratory beer the ?Championship...